查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1347759

2023-2028 年按治療、癌症類型（非小細胞肺癌、小細胞肺癌）、配銷通路和地區分類的肺癌治療市場報告

Lung Cancer Therapeutics Market Report by Therapy, Cancer Type (Non-small Cell Lung Cancer, Small Cell Lung Cancer ), Distribution Channel, and Region 2023-2028
出版日期: | 出版商: IMARC | 英文 145 Pages | 商品交期: 2-3個工作天內

價格

市場概況：

2022年，全球肺癌治療市場規模達到272.216億美元。展望未來，IMARC Group預計到2028年該市場將達到502.33億美元，2023-2028年年複合成長率（CAGR）為10.90%。由於不健康的生活方式和過度吸煙，肺癌患病率不斷上升，個人對早期診斷和治療重要性的認知不斷提高，以及精準醫學的進步是推動市場的一些關鍵因素。

肺癌治療是指用於控制和治療肺癌症狀的各種治療方案，包括呼吸短促、胸痛、喘息和咳血。其中包括有助於減少和破壞肺部癌性腫瘤生長的藥物和手術。它們還涉及針對癌細胞特定基因突變或改變並刺激免疫系統對抗疾病的療法。目前，由於吸煙產品消費的增加、污染程度的上升以及不健康的飲食模式，肺癌患病率不斷上升，這促進了對有效肺癌治療方法的需求。

肺癌治療市場趨勢：

目前，人們對癌症早期診斷和治療益處的認知不斷提高，這是提供良好市場前景的關鍵因素之一。除此之外，提供個性化治療選擇並改善患者治療效果的靶向療法的開發也有利於市場成長。分子測試和基因分析能夠識別肺癌細胞中的特定突變和生物標記。與此相一致的是，擴大使用奈米藥物，通過增強療效和減少副作用來提高抗癌藥物向受影響組織的有效遞送。此外，擴大使用免疫檢查點抑製劑（ICIs）作為單一療法或與其他療法聯合使用，正在創造積極的市場前景。此外，聯合療法（涉及同時使用多種治療方式）的日益普及正在加強市場成長。除此之外，液體活體組織切片的廣泛使用正在推動市場的發展，液體活體組織切片涉及血液樣本中循環腫瘤脫氧核糖核酸（DNA）和其他生物標記的分析。液體活體組織切片是一種評估腫瘤突變狀態和治療反應的非侵入性方法，從而能夠即時監測和調整治療。此外，製藥公司、研究機構和醫療保健提供者之間開發創新療法和藥物的戰略合作正在推動市場成長。與此同時，肺癌新型治療方式、藥物輸送系統和診斷工具的持續研究和技術進步預計將刺激市場成長。

本報告回答的關鍵問題：

  • 迄今為止，全球肺癌治療市場表現如何，未來幾年將如何表現？
  • 全球肺癌治療市場的促進因素、限制因素和機遇是什麼？
  • 每個促進因素、限制因素和機遇對全球肺癌治療市場有何影響？
  • 主要區域市場有哪些？
  • 哪些國家代表了最具吸引力的肺癌治療市場？
  • 基於該療法的市場細分是什麼？
  • 肺癌治療市場上哪種療法最具吸引力？
  • 根據癌症類型分類的市場是怎樣的？
  • 肺癌治療市場中哪種癌症類型最具吸引力？
  • 基於配銷通路的市場細分是什麼？
  • 肺癌治療市場中最具吸引力的配銷通路是什麼？
  • 全球肺癌治療市場的競爭格局如何？
  • 誰是全球肺癌治療市場的主要參與者/公司？

目錄

第一章：前言

第 2 章：範圍和方法

  • 研究目的
  • 利益相關者
  • 數據源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球肺癌治療市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：通過療法進行市場細分

  • 標靶治療
    • 市場走向
    • 關鍵環節
      • 貝伐珠單抗
      • 達拉非尼/曲美替尼
      • 鹽酸厄洛替尼
      • 奧西替尼
      • 其他
    • 市場預測
  • 免疫療法
    • 市場走向
    • 關鍵環節
      • 杜瓦魯單抗
      • 納武單抗
      • 阿替珠單抗
      • 派姆單抗
    • 市場預測
  • 放射治療
    • 市場走向
    • 關鍵環節
      • 外梁
      • 內梁
      • 系統性
    • 市場預測
  • 化療
    • 市場走向
    • 市場預測

第 7 章：按癌症類型分類的市場細分

  • 非小細胞肺癌（NSCLC）
    • 市場走向
    • 市場預測
  • 小細胞肺癌 (SCLC)
    • 市場走向
    • 市場預測

第 8 章：按配銷通路分類的市場細分

  • 醫院藥房
    • 市場走向
    • 市場預測
  • 零售藥店
    • 市場走向
    • 市場預測
  • 網上藥店
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：按地區分類的市場細分

  • 北美
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳大利亞
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 按國家/地區分類的市場細分
    • 市場預測

第 10 章：促進因素、限制和機會

  • 概述
  • 動力
  • 限制
  • 機會

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca Plc
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company Limited
    • Eli Lilly and Company
    • GSK PLC
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Roche Holding AG
    • Takeda Pharmaceutical Company Limited
Product Code: SR112023A8336

Market Overview:

The global lung cancer therapeutics market size reached US$ 27,221.60 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 50,233 Million by 2028, exhibiting a growth rate (CAGR) of 10.90% during 2023-2028. The rising prevalence of lung cancer due to unhealthy lifestyles and excessive smoking, increasing awareness among individuals about the importance of early diagnosis and treatment, and advancements in precision medicine represent some of the key factors driving the market.

Lung cancer therapeutics refer to various treatment options used for managing and treating the symptoms of lung cancer, which include shortness of breath, chest pain, wheezing, and coughing up blood. They include medications and surgery that help reduce and destroy the growth of cancerous tumors in the lungs. They also involve therapies that focus on specific genetic mutations or alterations in cancer cells and stimulate the immune system to fight against the disease. At present, the growing prevalence of lung cancer on account of the increasing consumption of smoking products, rising pollution level, and unhealthy dietary patterns is catalyzing the demand for effective lung cancer therapeutics.

Lung Cancer Therapeutics Market Trends:

The rising awareness among individuals about the benefits of early diagnosis and treatment of cancer currently represents one of the key factors offering a favorable market outlook. Apart from this, the development of targeted therapies that offer personalized treatment options and improve patient outcomes are favoring market growth. Molecular testing and genetic profiling enable the identification of specific mutations and biomarkers in lung cancer cells. In line with this, the increasing use of nanomedicine to increase the efficient delivery of the anticancer drug to the affected tissues by enhancing the efficacy and reducing the side effects. Furthermore, the increasing use of immune checkpoint inhibitors (ICIs) as monotherapy or in combination with other therapies is creating a positive market outlook. Additionally, the rising adoption of combination therapies, which involve the simultaneous use of multiple treatment modalities, is strengthening the market growth. Besides this, the expanding utilization of liquid biopsies, which involve the analysis of circulating tumor deoxyribonucleic acid (DNA) and other biomarkers in blood samples, is driving the market. Liquid biopsies act as a non-invasive method of assessing tumor mutational status and treatment response, thereby enabling real-time monitoring and adjustment of therapy. Moreover, strategic collaborations between pharmaceutical companies, research institutions, and healthcare providers to develop innovative therapies and drugs are propelling market growth. Along with this, ongoing research and technological advancements in novel treatment modalities, drug delivery systems, and diagnostic tools for lung cancer are expected to stimulate market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global lung cancer therapeutics market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on therapy, cancer type, and distribution channel.

Therapy Insights:

Targeted Therapy

Bevacizumab

Dabrafenib/Trametinib

Erlotinib Hydrochloride

Osimertinib

Others

Immunotherapy

Durvalumab

Nivolumab

Atezolizumab

Pembrolizumab

Radiation Therapy

External Beam

Internal Beam

Systemic

Chemotherapy

The report has provided a detailed breakup and analysis of the lung cancer therapeutics market based on the therapy. This includes targeted therapy (bevacizumab, dabrafenib/trametinib, erlotinib hydrochloride, Osimertinib and others); immunotherapy (durvalumab, nivolumab, atezolizumab and pembrolizumab); radiation therapy (external beam, internal beam and systemic); and chemotherapy. According to the report, targeted therapy represented the largest segment.

Cancer Type Insights:

Non-small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

A detailed breakup and analysis of the lung cancer therapeutics market based on the cancer type has also been provided in the report. This includes non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC). According to the report, non-small cell lung cancer (NSCLC) accounted for the largest market share.

Distribution Channel Insights:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

The report has provided a detailed breakup and analysis of the lung cancer therapeutics market based on the distribution channel. This includes hospital pharmacies, retail pharmacies, online pharmacies, and others. According to the report, hospital pharmacies represented the largest segment.

Regional Insights:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for lung cancer therapeutics. Some of the factors driving the North America lung cancer therapeutics market included the increasing prevalence of lung cancer, rising awareness among individuals about the benefits of early diagnosis and treatment, technological advancements in treatment procedures, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global lung cancer therapeutics market. Detailed profiles of all major companies have been provided. Some of the companies covered include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Eli Lilly and Company, GSK PLC, Merck & Co. Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Takeda Pharmaceutical Company Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global lung cancer therapeutics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global lung cancer therapeutics market?
  • What is the impact of each driver, restraint, and opportunity on the global lung cancer therapeutics market?
  • What are the key regional markets?
  • Which countries represent the most attractive lung cancer therapeutics market?
  • What is the breakup of the market based on the therapy?
  • Which is the most attractive therapy in the lung cancer therapeutics market?
  • What is the breakup of the market based on the cancer type?
  • Which is the most attractive cancer type in the lung cancer therapeutics market?
  • What is the breakup of the market based on the distribution channel?
  • Which is the most attractive distribution channel in the lung cancer therapeutics market?
  • What is the competitive structure of the global lung cancer therapeutics market?
  • Who are the key players/companies in the global lung cancer therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Lung Cancer Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapy

  • 6.1 Targeted Therapy
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Bevacizumab
      • 6.1.2.2 Dabrafenib/Trametinib
      • 6.1.2.3 Erlotinib Hydrochloride
      • 6.1.2.4 Osimertinib
      • 6.1.2.4 Others
    • 6.1.2 Market Forecast
  • 6.2 Immunotherapy
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Durvalumab
      • 6.2.2.2 Nivolumab
      • 6.2.2.3 Atezolizumab
      • 6.2.2.4 Pembrolizumab
    • 6.2.2 Market Forecast
  • 6.3 Radiation Therapy
    • 6.3.1 Market Trends
    • 6.3.2 Key Segment
      • 6.3.2.1 External Beam
      • 6.3.2.2 Internal Beam
      • 6.3.2.3 Systemic
    • 6.3.2 Market Forecast
  • 6.4 Chemotherapy
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Cancer Type

  • 7.1 Non-small Cell Lung Cancer (NSCLC)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Small Cell Lung Cancer (SCLC)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Pharmacies
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Amgen Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 AstraZeneca Plc
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Boehringer Ingelheim International GmbH
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Bristol-Myers Squibb Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Daiichi Sankyo Company Limited
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Eli Lilly and Company
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 GSK PLC
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Merck & Co. Inc.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Novartis AG
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
    • 14.3.11 Pfizer Inc.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
    • 14.3.12 Roche Holding AG
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
    • 14.3.13 Takeda Pharmaceutical Company Limited
      • 14.3.13.1 Company Overview
      • 14.3.13.2 Product Portfolio

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Lung Cancer Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Lung Cancer Therapeutics Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Lung Cancer Therapeutics Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Lung Cancer Therapeutics Market: Breakup by Therapy (in %), 2022
  • Figure 5: Global: Lung Cancer Therapeutics Market: Breakup by Cancer Type (in %), 2022
  • Figure 6: Global: Lung Cancer Therapeutics Market: Breakup by Distribution Channel (in %), 2022
  • Figure 7: Global: Lung Cancer Therapeutics Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Lung Cancer Therapeutics (Targeted Therapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Lung Cancer Therapeutics (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Lung Cancer Therapeutics (Immunotherapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Lung Cancer Therapeutics (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Lung Cancer Therapeutics (Radiation Therapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Lung Cancer Therapeutics (Radiation Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Lung Cancer Therapeutics (Chemotherapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Lung Cancer Therapeutics (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Lung Cancer Therapeutics (Non-small Cell Lung Cancer (NSCLC)) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Lung Cancer Therapeutics (Non-small Cell Lung Cancer (NSCLC)) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Lung Cancer Therapeutics (Small Cell Lung Cancer (SCLC)) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Lung Cancer Therapeutics (Small Cell Lung Cancer (SCLC)) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Lung Cancer Therapeutics (Hospital Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Lung Cancer Therapeutics (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Lung Cancer Therapeutics (Retail Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Lung Cancer Therapeutics (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Lung Cancer Therapeutics (Online Pharmacies) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Lung Cancer Therapeutics (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Lung Cancer Therapeutics (Other Distribution Channels) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Lung Cancer Therapeutics (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: North America: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: North America: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: United States: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: United States: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Canada: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Canada: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: Asia-Pacific: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: Asia-Pacific: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: China: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: China: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: Japan: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: Japan: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: India: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: India: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: South Korea: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: South Korea: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Australia: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Australia: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: Indonesia: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: Indonesia: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Others: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Others: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: Europe: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: Europe: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: Germany: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: Germany: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: France: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: France: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: United Kingdom: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: United Kingdom: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Italy: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Italy: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Spain: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Spain: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Russia: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Russia: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: Others: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: Others: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: Latin America: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: Latin America: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Brazil: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Brazil: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Mexico: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Mexico: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Others: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Others: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Middle East and Africa: Lung Cancer Therapeutics Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Middle East and Africa: Lung Cancer Therapeutics Market: Breakup by Country (in %), 2022
  • Figure 76: Middle East and Africa: Lung Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 77: Global: Lung Cancer Therapeutics Industry: Drivers, Restraints, and Opportunities
  • Figure 78: Global: Lung Cancer Therapeutics Industry: Value Chain Analysis
  • Figure 79: Global: Lung Cancer Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Lung Cancer Therapeutics Market: Key Industry Highlights, 2022 & 2028
  • Table 2: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Therapy (in Million US$), 2023-2028
  • Table 3: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Cancer Type (in Million US$), 2023-2028
  • Table 4: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Distribution Channel (in Million US$), 2023-2028
  • Table 5: Global: Lung Cancer Therapeutics Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Lung Cancer Therapeutics Market: Competitive Structure
  • Table 7: Global: Lung Cancer Therapeutics Market: Key Players